Receptor Nomenclature | NR2B1 |
Receptor code | 4.1:RX:2:B1 |
Molecular information | Hs:462aa, P19793, chr. 9q34.31–3 |
| Rn:467aa, P287004 |
| Mm: 467aa, Q05343, chr. 25–8 |
DNA binding | |
Structure | Homodimer, heterodimer, RXR partner |
HRE core sequence | AGGTCA (DR-1, DR-2, DR-3, DR-4, DR-5) |
Partners | TR2 and TR4 (physical, functional): DNA binding7,9,10 ; VDR (physical, functional): DNA binding9,10; RARα, RARβ, and RARγ (physical, functional): DNA binding7,9–14; PPARα, PPARβ, and PPARγ (physical, functional): DNA binding15,16; LXRα and LXRβ (physical, functional): DNA binding17–20; FXR (physical, functional): DNA binding21; PXR (physical, functional): DNA binding22–25; CAR (physical, functional): DNA binding26,27; NGFI-B (physical, functional): DNA binding28,29; NURR1 (physical, functional): DNA binding29 |
Agonists | CD3254 (3 nM), LG100268 (3.2 nM), LGD1069 (36 nM),* 9-cis-retinoic acid (6.7–73 nM),* methoprenic acid (2 μM) [IC50]8,12,30–39; AGN194204 (0.4 nM) [Kd]40; SR11237, docosahexaenoic acid, phytanic acid41–44 |
Antagonists | LG100754 (3.4 nM) [IC50]36,45,46; PA451, UVI300347,48 |
Coactivators | NCOA1, NCOA2, NCOA3, PGC-1α, PPARBP, TBP, TAFII110, TAFII28, CREBBP, p30036,49–59 |
Biologically important isoforms | RXRα1 {Mm}: differs from RXRα2 in the A/B domain60; RXRα2 {Mm}: specifically expressed in testis60 |
Tissue distribution | Liver, lung, muscle, kidney, epidermis, and intestine; major isotype in the skin {Hs, Mm, Rn} [Northern blot, in situ hybridization, Western blot]3,8,61 |
Functional assays | Differentiation of 3T3-L1 cells to adipocytes measured by the accumulation of triglyceride produced within the cytoplasm of the adipocyte {Mm}33,62,63 ; induction of apoptosis (associated with RARα activation) in leukemia cell lines {Hs}38,64; primitive endodermal differentiation and morphological differentiation in F9 murine embryonal carcinoma cell line {Mm}65,66 |
Mutant phenotype | Knockout mice have hypoplasia of the myocardium, which leads to animal death due to cardiac failure at around embryonic day 14.5; animals also have ocular malformation {Mm} [knockout]51,67–73 |